Infectious disease specialist, Dr. Shmuel Shoham, will briefly present some of the newest clinical updates and guidance, with the remainder of the event being dedicated to answering audience questions about COVID-19 and CLL/SLL.
Eight years ago this month, I was diagnosed with chronic lymphocytic leukemia (CLL). My world turned upside down. I knew nothing about CLL but had to get smart on the subject. And I did this with the help of good doctors and organizations such as the CLL Society.
CLL Society believes that every immunocompromised individual, including those with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), regardless of treatment status, should experience easy access to the life-saving pre-exposure prophylaxis therapy or PreP, Evusheld.
At the annual meeting of the American Society of Hematology (ASH) 2021, our own Dr. Brian Koffman, interviewed Dr. Stephan Stilgenbauer, Professor of Medicine at the Comprehensive Cancer Center at Ulm University in Germany. They discussed the latest results from the GAIA (CLL13) trial, which compared rates of measurable
These results are encouraging and show that patients with relapsed/refractory B-cell NHL treated with bispecific LV20.19 CAR T-cells have a high overall response rate and low rates of grade ≥3 CRS or ICANS.